|
|
 |
|
Viewing report
|
|
|
|
Generic Pharmaceuticals Market – A Global Analysis
Frost & Sullivan, Dec 2011, Pages: 213
Time is Ripe for Generics Manufacturers as Key Blockbuster Drugs Set to go Off-patent
The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs and the judicious cost containment efforts of governments and healthcare service providers, worldwide. At the same time, the balance in terms of healthcare expenditure and sales revenue is poised to shift from developed to emerging markets such as India, China, Brazil, Russia, Turkey and South Korea, as huge potential still remains untapped in these countries.
“The patent expiry of several major blockbuster drugs worth $150 billion between 2010 and 2017 will fuel the growth of the global generic pharmaceuticals market,” notes the analyst of this research. “The trend is shifting towards less competitive, yet commercially attractive, segments such as difficult-to-produce generics, specialty generics and biosimilars.” Leading global generic pharmaceuticals manufacturers have been proactive in forging strategic alliances with branded pharmaceutical companies for marketing rights and exclusivity in producing generic versions of blockbuster drugs such as LIPITOR, Cozaar and Crestor, among others. Market leaders such as Teva, Sandoz and Mylan are increasingly focused on biosimilars, as this segment provides a competitive edge and presents huge profit margins.
Curbs on Healthcare Expenditures to Result in Intensified Competition
While these are positive signs for market participants, a potential dampener is the progressively stringent regulations and price control measures being imposed by governments. These have tended to squeeze profit margins for generic manufacturers. “The increase in the prevalence of chronic disorders, newly reported diseases and ageing populations have resulted in tremendous pressure being placed on governments to implement cost containment measures and curb rampant healthcare expenditure,” adds the analyst.
As competition intensifies, generic drug manufacturers will have to make careful choices about the product segments that they wish to compete in and the appropriate time of entry into the market. “Large multinational generic firms need to adopt a differentiated approach by opting for products with technologically challenging formulations, products which require significant regulatory support and products with limited availability of active pharmaceutical ingredients (APIs),” advises the analyst. “Small and medium-sized firms should focus on products with relatively higher profit margins.”
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following geographic areas in this research:
- United States
- Europe (Germany, the United Kingdom, Spain, Italy and France)
- India
- China
This Frost & Sullivan research service titled Generic Pharmaceuticals Market – A Global Analysis provides a comprehensive overview of market drivers, restraints and challenges faced by industry participants. The base year is 2010 with forecasts running through 2017. The geographic segments covered include: the United States, Europe (Germany, the United Kingdom, France, Spain, and Italy), India and China.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
